@article{ChanJaladankiSomanietal.2021, author = {Chan, Lili and Jaladanki, Suraj K. and Somani, Sulaiman and Paranjpe, Ishan and Kumar, Arvind and Zhao, Shan and Kaufman, Lewis and Leisman, Staci and Sharma, Shuchita and He, John Cijiang and Murphy, Barbara and Fayad, Zahi A. and Levin, Matthew A. and B{\"o}ttinger, Erwin and Charney, Alexander W. and Glicksberg, Benjamin and Coca, Steven G. and Nadkarni, Girish N.}, title = {Outcomes of patients on maintenance dialysis hospitalized with COVID-19}, series = {Clinical journal of the American Society of Nephrology : CJASN}, volume = {16}, journal = {Clinical journal of the American Society of Nephrology : CJASN}, number = {3}, publisher = {American Society of Nephrology}, address = {Washington}, organization = {Mount Sinai Covid I}, issn = {1555-9041}, doi = {10.2215/CJN.12360720}, pages = {452 -- 455}, year = {2021}, language = {en} } @misc{DellepianeVaidJaladankietal.2021, author = {Dellepiane, Sergio and Vaid, Akhil and Jaladanki, Suraj K. and Coca, Steven and Fayad, Zahi A. and Charney, Alexander W. and B{\"o}ttinger, Erwin and He, John Cijiang and Glicksberg, Benjamin S. and Chan, Lili and Nadkarni, Girish}, title = {Acute kidney injury in patients hospitalized with COVID-19 in New York City}, series = {Zweitver{\"o}ffentlichungen der Universit{\"a}t Potsdam : Reihe der Digital Engineering Fakult{\"a}t}, journal = {Zweitver{\"o}ffentlichungen der Universit{\"a}t Potsdam : Reihe der Digital Engineering Fakult{\"a}t}, number = {5}, issn = {2590-0595}, doi = {10.25932/publishup-58541}, url = {http://nbn-resolving.de/urn:nbn:de:kobv:517-opus4-585415}, pages = {5}, year = {2021}, language = {en} } @article{VaidChanChaudharyetal.2021, author = {Vaid, Akhil and Chan, Lili and Chaudhary, Kumardeep and Jaladanki, Suraj K. and Paranjpe, Ishan and Russak, Adam J. and Kia, Arash and Timsina, Prem and Levin, Matthew A. and He, John Cijiang and B{\"o}ttinger, Erwin and Charney, Alexander W. and Fayad, Zahi A. and Coca, Steven G. and Glicksberg, Benjamin S. and Nadkarni, Girish N.}, title = {Predictive approaches for acute dialysis requirement and death in COVID-19}, series = {Clinical journal of the American Society of Nephrology : CJASN}, volume = {16}, journal = {Clinical journal of the American Society of Nephrology : CJASN}, number = {8}, publisher = {American Society of Nephrology}, address = {Washington}, organization = {MSCIC}, issn = {1555-9041}, doi = {10.2215/CJN.17311120}, pages = {1158 -- 1168}, year = {2021}, abstract = {Background and objectives AKI treated with dialysis initiation is a common complication of coronavirus disease 2019 (COVID-19) among hospitalized patients. However, dialysis supplies and personnel are often limited. Design, setting, participants, \& measurements Using data from adult patients hospitalized with COVID-19 from five hospitals from theMount Sinai Health System who were admitted between March 10 and December 26, 2020, we developed and validated several models (logistic regression, Least Absolute Shrinkage and Selection Operator (LASSO), random forest, and eXtreme GradientBoosting [XGBoost; with and without imputation]) for predicting treatment with dialysis or death at various time horizons (1, 3, 5, and 7 days) after hospital admission. Patients admitted to theMount Sinai Hospital were used for internal validation, whereas the other hospitals formed part of the external validation cohort. Features included demographics, comorbidities, and laboratory and vital signs within 12 hours of hospital admission. Results A total of 6093 patients (2442 in training and 3651 in external validation) were included in the final cohort. Of the different modeling approaches used, XGBoost without imputation had the highest area under the receiver operating characteristic (AUROC) curve on internal validation (range of 0.93-0.98) and area under the precisionrecall curve (AUPRC; range of 0.78-0.82) for all time points. XGBoost without imputation also had the highest test parameters on external validation (AUROC range of 0.85-0.87, and AUPRC range of 0.27-0.54) across all time windows. XGBoost without imputation outperformed all models with higher precision and recall (mean difference in AUROC of 0.04; mean difference in AUPRC of 0.15). Features of creatinine, BUN, and red cell distribution width were major drivers of the model's prediction. Conclusions An XGBoost model without imputation for prediction of a composite outcome of either death or dialysis in patients positive for COVID-19 had the best performance, as compared with standard and other machine learning models.}, language = {en} } @article{ChanChaudharySahaetal.2021, author = {Chan, Lili and Chaudhary, Kumardeep and Saha, Aparna and Chauhan, Kinsuk and Vaid, Akhil and Zhao, Shan and Paranjpe, Ishan and Somani, Sulaiman and Richter, Felix and Miotto, Riccardo and Lala, Anuradha and Kia, Arash and Timsina, Prem and Li, Li and Freeman, Robert and Chen, Rong and Narula, Jagat and Just, Allan C. and Horowitz, Carol and Fayad, Zahi and Cordon-Cardo, Carlos and Schadt, Eric and Levin, Matthew A. and Reich, David L. and Fuster, Valentin and Murphy, Barbara and He, John C. and Charney, Alexander W. and B{\"o}ttinger, Erwin and Glicksberg, Benjamin and Coca, Steven G. and Nadkarni, Girish N.}, title = {AKI in hospitalized patients with COVID-19}, series = {Journal of the American Society of Nephrology : JASN}, volume = {32}, journal = {Journal of the American Society of Nephrology : JASN}, number = {1}, publisher = {American Society of Nephrology}, address = {Washington}, organization = {Mt Sinai COVID Informatics Ct}, issn = {1046-6673}, doi = {10.1681/ASN.2020050615}, pages = {151 -- 160}, year = {2021}, abstract = {Background: Early reports indicate that AKI is common among patients with coronavirus disease 2019 (COVID-19) and associatedwith worse outcomes. However, AKI among hospitalized patients with COVID19 in the United States is not well described. Methods: This retrospective, observational study involved a review of data from electronic health records of patients aged >= 18 years with laboratory-confirmed COVID-19 admitted to the Mount Sinai Health System from February 27 to May 30, 2020. We describe the frequency of AKI and dialysis requirement, AKI recovery, and adjusted odds ratios (aORs) with mortality. Results: Of 3993 hospitalized patients with COVID-19, AKI occurred in 1835 (46\%) patients; 347 (19\%) of the patientswith AKI required dialysis. The proportionswith stages 1, 2, or 3 AKIwere 39\%, 19\%, and 42\%, respectively. A total of 976 (24\%) patients were admitted to intensive care, and 745 (76\%) experienced AKI. Of the 435 patients with AKI and urine studies, 84\% had proteinuria, 81\% had hematuria, and 60\% had leukocyturia. Independent predictors of severe AKI were CKD, men, and higher serum potassium at admission. In-hospital mortality was 50\% among patients with AKI versus 8\% among those without AKI (aOR, 9.2; 95\% confidence interval, 7.5 to 11.3). Of survivors with AKI who were discharged, 35\% had not recovered to baseline kidney function by the time of discharge. An additional 28 of 77 (36\%) patients who had not recovered kidney function at discharge did so on posthospital follow-up. Conclusions: AKI is common among patients hospitalized with COVID-19 and is associated with high mortality. Of all patients with AKI, only 30\% survived with recovery of kidney function by the time of discharge.}, language = {en} } @article{DellepianeVaidJaladankietal.2021, author = {Dellepiane, Sergio and Vaid, Akhil and Jaladanki, Suraj K. and Coca, Steven and Fayad, Zahi A. and Charney, Alexander W. and B{\"o}ttinger, Erwin and He, John Cijiang and Glicksberg, Benjamin S. and Chan, Lili and Nadkarni, Girish}, title = {Acute kidney injury in patients hospitalized with COVID-19 in New York City}, series = {Kidney medicine}, volume = {3}, journal = {Kidney medicine}, number = {5}, publisher = {Elsevier}, address = {Amsterdam}, issn = {2590-0595}, doi = {10.1016/j.xkme.2021.06.008}, pages = {877 -- 879}, year = {2021}, language = {en} }